# MPD-RC 112 (NCT01259856)

> Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

No report yet. It can be ordered.

- Drugs tested: pegylated interferon alfa-2a
- Indication: high-risk polycythemia vera and essential thrombocythemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01259856
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Ronald Hoffman
- Conditions: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
- Interventions: PEGASYS; Hydroxyurea; Aspirin
- Enrollment: 168
- Primary outcome: Number of Participants With Complete Remission (CR)
- Primary outcome: Number of Participants With Partial Remission (PR)

## Indexed commentary on MPD-RC 112 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 3
- X threads: 3
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mpd-rc-112-nct01259856